Drug
Niraparib clinical trials
Also written Zejula, MK-4827 and JNJ-64091742.
- studies test it
- 158
- open now
- 32
- in phase 3
- 20
- first study started
- 2008
Keep track of what changes. Save the niraparib studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
158 studies that test it; most in 2020 (26)
| Year | Studies |
|---|---|
| 2008 | 1 |
| 2010 | 4 |
| 2011 | 1 |
| 2013 | 1 |
| 2014 | 1 |
| 2015 | 2 |
| 2016 | 6 |
| 2017 | 10 |
| 2018 | 13 |
| 2019 | 25 |
| 2020 | 26 |
| 2021 | 17 |
| 2022 | 18 |
| 2023 | 17 |
| 2024 | 10 |
| 2025 | 5 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 3
- Phase 1
- 49
- Phase 2
- 99
- Phase 3
- 20
- Phase 4
- 4
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 50 · Other 108
Tesaro, Inc. (19) · Massachusetts General Hospital (6) · GlaxoSmithKline (6) · M.D. Anderson Cancer Center (5) · Janssen Research & Development, LLC (5) · Zai Lab (Shanghai) Co., Ltd. (5) · Hoffmann-La Roche (3) · University Health Network, Toronto (3)
Often tested with
Tested in the same studies.
Dostarlimab (27) · Atezolizumab (7) · Abiraterone (7) · Bevacizumab (7) · Abiraterone Acetate (6) · Trastuzumab (6) · Paclitaxel (5) · Carboplatin (5)
Studies
Open first, then newest update. How each study uses niraparib is read from its arms, and is right about nine times in ten.
Testing it · 158
- Maintenance Niraparib Plus Ipilimumab in Patients With Metastatic Pancreatic Adenocarcinoma Whose Disease Has Not Progressed on Platinum-Based ChemotherapyRecruitingPhase 2Abramson Cancer Center at Penn MedicineNCT06747845Written as Niraparib
- Niraparib Maintenance in HRD-Positive Advanced Ovarian Cancer Following Front-Line Chemotherapy + BevacizumabRecruitingPhase 2Peking University Cancer Hospital & InstituteNCT06141265Written as Niraparib
- Recurrent Ovarian CarcinoSarcoma Anti-pd-1 NiraparibRecruitingPhase 2/3ARCAGY/ GINECO GROUPNCT03651206Written as Niraparib
- Genomic Biomarker-Selected Umbrella Neoadjuvant Study for High Risk Localized Prostate CancerRecruitingPhase 2University of British ColumbiaNCT04812366Written as Niraparib 100mg Oral Capsule
- Study Evaluating Safety, Tolerability, and Metabolism of NiraparibRecruitingPhase 4University of MiamiNCT06412120Written as Niraparib
- SBRT Alone or Followed by Niraparib for Oligometastases or Oligoprogression in Ovarian Cancer Following PARPi TherapyRecruitingPhase 2Institute of Cancer Research, United KingdomNCT05990192Written as Niraparib oral capsule
- A Long-term Treatment Extension Study of Niraparib in Participants Who Completed a Prior GlaxoSmithKline/TESARO-sponsored Niraparib StudyRecruitingPhase 2GlaxoSmithKlineNCT04641247Written as Niraparib
- Androgen Ablation Therapy With or Without Niraparib After Radiation Therapy for the Treatment of High-Risk Localized or Locally Advanced Prostate CancerRecruitingPhase 2M.D. Anderson Cancer CenterNCT04947254Written as Niraparib
- Combination Therapy in Cancers With Mutations in DNA Repair GenesRecruitingPhase 1University of California, San FranciscoNCT05694715Written as Niraparib
- Niraparib Added to Anti-PD-L1 Antibody Maintenance in SLFN11-positive, Extensive-disease SCLCRecruitingPhase 2ETOP IBCSG Partners FoundationNCT05718323Written as Niraparib
- Personalized Medicine for Advanced Biliary Cancer PatientsRecruitingPhase 3UNICANCERNCT05615818Written as Niraparib
- Liquid-biopsy Informed Platform Trial to Evaluate CDK4/6-inhibitor Resistant ER+/HER2- Metastatic Breast CancerRecruitingPhase 2Canadian Cancer Trials GroupNCT05601440Written as Niraparib
- I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast CancerRecruitingPhase 2QuantumLeap Healthcare CollaborativeNCT01042379Written as Dan222 + Niraparib
- Niraparib Rechallenge After Surgery in Ovarian Cancer Patients With Oligometastatic ProgressionRecruitingPhase 2MedSIRNCT06180356Written as Niraparib oral tablets
- Phase II Trial of the PARP Inhibitor Niraparib and PD-1 Inhibitor Dostarlimab in Patients With Advanced Cancers With Active Progressing Brain Metastases (STARLET)RecruitingPhase 2M.D. Anderson Cancer CenterNCT05700721Written as Niraparib
- Study of the Combination Dostarlimab With Niraparib In Patients With Penile CarcinomaRecruitingPhase 2H. Lee Moffitt Cancer Center and Research InstituteNCT05526989Written as Niraparib
- ProTarget - A Danish Nationwide Clinical Trial on Targeted Cancer Treatment Based on Genomic ProfilingRecruitingPhase 2Ulrik LassenNCT04341181Written as Niraparib
- ProBio: A Biomarker Driven Study in Patients With Metastatic Prostate CancerRecruitingPhase 3Karolinska InstitutetNCT03903835Written as Niraparib plus Abiraterone acetate plus Prednisone
- A Study of Niraparib in Combination With Abemaciclib for Late Line Treatment of Ovarian Cancer (NICHOL TRIAL)RecruitingPhase 1/2Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoNCT06594679Written as Niraparib Tosylate Monohydrate
- A Trial to Evaluate the Safety of Niraparib Tablets in Adult Female Participants With Advanced or Relapsed Epithelial Ovarian CancerNot yet recruitingPhase 4GlaxoSmithKlineNCT06887933Written as Niraparib
See all 158 studies that test niraparib →
Given in every arm · 25 — niraparib is usual care beside what is tested
- Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal CancerRecruitingPhase 3ImunonNCT06915025Written as Niraparib
- A Phase I/II Study of LM-2417 in Subjects With Advanced Solid TumoursRecruitingPhase 1/2LaNova Medicines LimitedNCT06682780Written as Niraparib
- Niraparib With beVAcizumab After Complete cytoreductioN in Patients With ovArian CancerRecruitingPhase 2ARCAGY/ GINECO GROUPNCT05183984Written as Niraparib
- Niraparib vs Niraparib Plus Bevacizumab in Patients With Platinum/Taxane-based Chemotherapy in Advanced Ovarian CancerRecruitingPhase 3AGO Study GroupNCT05009082Written as Niraparib
- Surgery and Niraparib in Secondary Recurrent Ovarian Cancer (SOC-3 Trial)RecruitingPhase 2Shanghai Gynecologic Oncology GroupNCT03983226Written as Niraparib
- A Study of Niraparib Combination Therapies for the Treatment of Metastatic Castration-Resistant Prostate CancerActive, not recruitingPhase 2Janssen Research & Development, LLCNCT03431350Written as Niraparib 200 mg
- Tuvusertib (M1774) in Participants With Metastatic or Locally Advanced Unresectable Solid Tumors (DDRiver Solid Tumors 301)Active, not recruitingPhase 1EMD Serono Research & Development Institute, Inc.NCT04170153Written as Niraparib
- Two-cohort Study of Niraparib and Dostarlimab Plus (Chemo)RadIotherapy in Locally-Advanced Head and Neck Squamous Cell CarcinomaActive, not recruitingPhase 1/2Grupo Español de Tratamiento de Tumores de Cabeza y CuelloNCT05784012Written as Niraparib
- Bevacizumab and/or Niraparib in Patients With Recurrent Endometrial and/or Ovarian Cancer With ARID1A MutationTerminatedPhase 2University of OklahomaNCT05523440Written as Niraparib
- A Multi-Center Trial of Androgen Suppression With Abiraterone Acetate, Leuprolide, PARP Inhibition and Stereotactic Body Radiotherapy in Prostate CancerActive, not recruitingPhase 1/2University of Michigan Rogel Cancer CenterNCT04194554Written as Niraparib
- Trial of Niraparib in Participants With Newly-diagnosed Glioblastoma and Recurrent GliomaActive, not recruitingEarly Phase 1Nader SanaiNCT05076513Written as Niraparib
- Abemaciclib and Niraparib Before Surgery for the Treatment of Hormone Receptor Positive HER2 Negative Breast CancerCompletedPhase 1OHSU Knight Cancer InstituteNCT04481113Written as Niraparib Tosylate Monohydrate
- A Study of ART4215 for the Treatment of Advanced or Metastatic Solid TumorsCompletedPhase 1Artios Pharma LtdNCT04991480Written as Niraparib
- Niraparib/TTFields in GBMActive, not recruitingPhase 2Abramson Cancer Center at Penn MedicineNCT04221503Written as Niraparib
- A Study to Evaluate the Efficacy and Safety of Novel Treatment Combinations in Participants With Ovarian CancerCompletedPhase 2Tesaro, Inc.NCT03574779Written as Niraparib
- European Trial on Enhanced DNA Repair Inhibition in Ovarian CancerCompletedPhase 2Universitaire Ziekenhuizen KU LeuvenNCT03783949Written as Niraparib
- Platinum-based Chemotherapy With Atezolizumab and Niraparib in Patients With Recurrent Ovarian CancerCompletedPhase 3Grupo Español de Investigación en Cáncer de OvarioNCT03598270Written as Niraparib
- A Dose-escalation Study of the Safety and Pharmacology of DAN-222 in Subjects With Metastatic Breast CancerCompletedPhase 1Dantari, Inc.NCT05261269Written as Niraparib
- Effects of Single Agent Niraparib and Niraparib Plus Programmed Cell Death-1 (PD-1) Inhibitors in Non-Small Cell Lung Cancer ParticipantsCompletedPhase 2Tesaro, Inc.NCT03308942Written as Niraparib
- Niraparib Versus Niraparib-bevacizumab Combination in Women With Platinum-sensitive Epithelial Ovarian CancerCompletedPhase 1/2Nordic Society of Gynaecological Oncology - Clinical Trials UnitNCT02354131Written as Niraparib
Showing 20 of 25.
Codes
What other systems call niraparib · ClinicalTrials.gg INT005538
- MeSH (NLM) C545685niraparibConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) HMC2H89N35NIRAPARIBConfirmed FDA, NLM, Wikidata
- RxNorm 1918231Confirmed FDA, Wikidata
- Wikidata Q25326660niraparibConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C80059NiraparibConfirmed FDA, Wikidata
- DrugBank DB11793One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C545685 | niraparib | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | HMC2H89N35 | NIRAPARIB | Confirmed FDA, NLM, Wikidata |
| RxNorm | 1918231 | — | Confirmed FDA, Wikidata |
| Wikidata | Q25326660 | niraparib | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C80059 | Niraparib | Confirmed FDA, Wikidata |
| DrugBank | DB11793 | — | One source Wikidata |
Also registered as niraparib hydrochloride (UNII L4JFC1PHCI) and niraparib tosylate (UNII 195Q483UZD).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.